During the course of HIV infection, some HIV-1 viruses switch from using the CCR5 (R5) coreceptor to using CXCR4 (X4). Here, we describe two subtype C isolates from a Zimbabwean patient that switched from using R5 to using both R5 and X4 with an accompanying addition of five amino acids to the V3 loop region of envelope. The insert appears to be derived from the human genome rather than a duplication within HIV-1.
Initial infection with HIV-1 occurs most often with viruses that utilize the chemokine coreceptor CCR5 (R5). However, in up to 50% of HIV-1 subtype B infections, envelope glycoproteins acquire amino acid changes that lead to using the coreceptor, CXCR4 (X4); this switch precedes progression to AIDS [1, 2] . The prevalence of X4 usage in subtype C HIV-1 viruses has been thought to be lower compared to subtype B HIV-1, but studies of X4-using subtype C viruses have become more common [3] [4] [5] [6] . The mechanism of coreceptor switch is unknown. Here, we report on subtype C virus isolates from an individual in Zimbabwe where, over 2 years, there was a switch from an R5 to X4 using virus that occurred concurrent with an unusual insert within the V3 loop of envelope.
A blood sample was first collected from a 36-year-old patient, TC02, in 2001 in Harare, Zimbabwe. Peripheral blood mononuclear cells (PBMCs) were cultivated with donor PBMCs and the virus isolate was characterized as using R5 through both an MT-2 assay and GHOST assay using fluorescence-activated cell sorting to identify infected cells [6] . A second blood sample was collected in 2003 and virus was grown from the PBMCs. This second virus isolate grew on MT-2 cells, forming syncytia, and used both R5 and X4 coreceptors in the GHOST assay. Over the 2 years between isolates, the CD4 þ cells increased from 9 to 81 and the viral load decreased from 5.09 log 10 copies RNA/ml to 3.94 log 10 copies RNA/ml on a nonsuppressive antiretroviral regimen, consisting of lamivudine, stavudine, and saquinavir. There was evidence for evolution of HIVassociated drug resistance in the second sample, with development of an L90M mutation in the viral protease and M184V in the viral reverse transcriptase compared to wild-type virus at baseline. Upon sequencing the C2-V5 region of both samples, we discovered that the second sample contained an unusual five amino acid insert within the V3 loop ( Fig. 1) . This insertion was observed in the primary isolate from 2003 as well as three biological clones obtained by limiting dilution of PBMCs infected with the initial isolate. The five amino acid insert, RSYTP, is located between amino acids 23 and 24, just after the crown region.
Insertions and deletions within the envelope V3 loop are common, especially among X4-using viruses. These insertions are usually one to three amino acids, and they often occur just before the crown region. Insertions have been reported in other HIV-1 genes and are frequently the result of duplications from other parts of the HIV-1 genome. For example, a five amino acid insert within reverse transcriptase was attributed to a duplication from the beginning of envelope [7] . However, a BLAST search of the HIV-1 Los Alamos database showed that the 15 nucleotides that comprise RSYTP are not found anywhere within the HIV-1 genome. A search of Genbank revealed that the sequence is found in the human genome. This sequence of 15 nucleotides is present in the transcription factor AP-2 on chromosome 6, as well as within chromosome 10. Sixteen nucleotides (the 15 and the next A nucleotide) are found in chromosome 16 . Shorter 13 and 14 base fragments are found throughout the human genome. Another explanation for the change in tropism may be the switch to lysine (K) and arginine (R) at positions 24 and 25, immediately 3' to the insert. The 2001 isolate contained neutral amino acids asperagine (N) and glycine (G) at these two positions. The insert increases the V3 loop length from 35 to 40 amino acids and increases the net charge. The K and R after the insert contribute to the increase in charge as well, resulting in an increase in net charge from þ5 to þ8. Analysis of the V3 loop amino acid sequence with the insert removed using WebPSSM (http://indra.mullins.microbiol.washington.edu/pssm/) predicts that the virus would be more likely to use R5 for entry, whereas the presence of positive amino acids at positions 24 and 25 is consistent with a virus that would also use X4 as a coreceptor.
These sequential isolates and the characterization of tropism in biologically cloned virus provides an example of an increase in V3 loop length and charge coinciding with a change in coreceptor usage, from an exclusively R5-using virus to a population capable of using both R5 and X4 for viral entry. The five amino acid insert adds an additional charged residue (R) and a second proline. Because of their unique R-group, prolines contribute to loop structures and increase flexibility in the secondary structures of peptides. This unique insert provides a further demonstration of the relationship between charged residues within the V3 loop, the increased flexibility of a 'promiscuous' envelope protein and the emergence of X4 and R5/X4 usage. The presence of the insert in the V3 loop of this virus increased both charge and flexibility, which suggests that the acquisition of host (human) sequences through recombination may lead to changes in tropism. However, more evidence is needed to prove the origin of this insert. Tenofovir (TFV) is a nucleotide analogue active against HIV and hepatitis B virus. Although TFV rarely affects the glomerular function, abnormalities in the kidney tubular function appear to be quite common. The relationship between TFV exposure and kidney tubular dysfunction (KTD) was examined prospectively in 92 HIV-infected individuals. Median TFV plasma trough concentration was higher in patients with KTD than in the rest (182 vs. 106 ng/ml; P U 0.001). This dosedependent effect further supports an involvement of TFV in KTD.
Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor widely used in the treatment of HIV infection. Although TFV is relatively well tolerated for the kidney with a very low rate of renal insufficiency [1] , cases of tubular dysfunction, including the development of Fanconi's syndrome, have been reported [2] [3] [4] [5] [6] [7] [8] ; and concern exists about its long-term use. TFV undergoes renal clearance by a combination of glomerular filtration and active tubular secretion. A mechanism of toxicity related with the route of elimination of TFV has been suggested. Polymorphisms at genes coding for transporter proteins involved on TFV elimination (ABCC2 or ABCC4 genes) have been associated with tubular renal damage. Examples of these polymorphisms are the haplotype 'CATC' at ABCC2 and the genotype CC at -24 ABCC2 [9, 10] . These studies suggest that alterations on TFV elimination could be the cause of renal toxicity, and that overexposure to TFV could cause kidney tubular cell damage. Herein, we analyse the association between TFV concentration and kidney tubular dysfunction (KTD) in HIV-infected patients under TFV therapy.
Patients included in this study belonged to a cohort of HIV-infected individuals followed for longer than 6 months at our institution [11] . The study protocol was approved by the hospital ethical committee. A total of 284 patients underwent study of KTD in 24-h urine. Patients were divided into three groups: patients under highly active antiretroviral therapy (HAART) containing TFV, n ¼ 154, patients under HAART without TFV, n ¼ 49; and antiretroviral-naive patients, n ¼ 81. The percentage of patients with KTD was higher in the group receiving TFV than in the rest (22% vs. 6% vs. 12%, P < 0.05). For the present substudy, only patients on TFV treatment were selected. KTD was determined on the basis of the following abnormalities [11] : nondiabetic glucosuria, altered resorption of phosphorus, hyperaminoaciduria, b2-microglobulinuria, and abnormal uric acid excretion. KTD was defined when at least two of these abnormalities were present, with at least one being a Fanconi's syndrome criteria (glucosuria in nondiabetics, hyperaminoaciduria or hyperphosphaturia). Mid-dose TFV concentration (C 12 ) was measured using a validated HPLC-mass method [12] . Time sample was between 10 and 14 h. Statistical analyses were performed using SPSS package, version 11.0 (SPSS Inc., Chicago, IL, USA).
Plasma samples and informed consent were obtained from 92 patients. Patients were divided into two groups: Eighteen (19%) fulfilling criteria for KTD and 74 (81%) with normal tubular function. The median exposure to TFV was 33 months (interquartile range ¼ 10-46). Creatinine clearance (24 h) was normal and comparable between groups. Moreover, both groups were well matched in sex, age, weight, hepatitis C virus coinfection, months under TFV, exposure to nephrotoxic drugs, concomitant protease inhibitors use, and hypertension. Diabetes was more frequent in cases than controls (44% vs. 22%; P ¼ 0.05).
Median TFV plasma levels were higher in patients with KTD than in those with normal tubular function [182 (105-220) vs. 106 (75-148) ng/ml, respectively; P ¼ 0.001] (Fig. 1 ). The best TFV plasma concentration threshold to discriminate KTD was 160 ng/ml (AUROC 0.75 [95% confidence interval (CI) ¼ 0.63-0.87], P ¼ 0.001) (61% sensitivity and 80% specificity). Multivariate analysis including all relevant variables showed that only TFV plasma levels more than 160 ng/ml were associated with KTD [odds ratio (OR) ¼ 4.8 (95% CI ¼ 1.5-16), P ¼ 0.008]. Interestingly, the multivariate analysis showed that female sex [OR ¼ 71 (95% CI ¼ 33-111), P < 0.01] and the ratio body weight/plasma
.01] were independently associated with higher TFV plasma levels.
These results argue in favour of a dose-dependent effect of TFV on KTD. This observation is in agreement with prior findings in which TFV concentration exceeded the one found in pharmacokinetic studies in patients with KTD [6, 13, 14] . The mechanism of kidney tubular damage by TFV is probably related with its renal clearance, supporting that higher TFV plasma levels may lead directly to a greater accumulation of TFV in the renal tubular cells and, consequently, to kidney toxicity [15] .
The ratio body weight/serum creatinine (BW/SCr) was associated with TFV plasma levels in our study. This finding agrees with a previous pharmacokinetic study in which a strong relationship was found between TFV clearance and BW/SCr, being TFV exposure diminished as the BW/SCr ratio increased [16] . Being female was also strongly associated with increased TFV exposure. Although sex differences in TFV plasma levels have not been reported so far, for other antiretrovirals such as zidovudine and lamivudine, differences in intracellular concentration of the triphosphate forms have been reported according to sex [17] .
KTD associated with TFV use appears to be multifactorial. Increased TFV exposure plays an important role, along with other factors, such as polymorphisms at renal transporter proteins, age, body weight, etc. [9, 10] . The ultimate mechanism of TFV kidney toxicity is still unclear because tenofovir has shown low mitochondrial toxicity in vitro, due to its low affinity for the polymerase gamma.
Several limitations of our study must be acknowledged. First, a limited number of patients were examined and we could have missed individuals with more serious renal toxicity manifested at early time points. Second, we only had one TFV measurement per patient and a relatively high intraindividual variation on TFV clearance has been described [18] . Lastly, the cross-sectional nature of our study warrants that results should be confirmed in larger, prospective studies.
In summary, these results suggest an association between TFV plasma levels and TFV-associated renal toxicity, primarily recognizable as kidney tubular dysfunction. This concentration-dependent effect is important because TFV may be used in conditions other than HIV (e.g. chronic hepatitis B) in which dose reduction might be an option. If tubular damage persists for long periods in the absence of renal insufficiency, laboratory and clinical manifestations other than those associated with kidney failure may develop (premature osteoporosis due to bone mineral loss) under long-term TFV therapy. Further studies examining the role of TFV plasma measurements to detect and prevent tubulopathy are warranted. 
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There are no conflicts of interests. In a cohort of 1950 HIV-positive men with known dates of HIV seroconversion, 399 developed tuberculosis. Mortality rates following tuberculosis were greatly increased (hazard ratio, adjusted for age at seroconversion, 4.7, 95% confidence interval 3.7-6.1), and this ratio was similar at different times following seroconversion. Overall mortality was similar to that in western seroconverter cohorts with much lower rates of tuberculosis, suggesting that tuberculosis is more a marker of HIV progression than a cause of it.
Biological evidence suggests that tuberculosis should hasten the progression of HIV infection [1] . However, the epidemiological evidence is less clear [1] [2] [3] . Although higher mortality following tuberculosis has been found [1, 4] , it is difficult to distinguish whether tuberculosis is a cause of the rapid progression or a marker of it. Two recent analyses using marginal structural models to adjust for other markers of progression without overadjusting concluded that the effect of tuberculosis on progression was probably causal [5, 6] . But, if getting tuberculosis is a marker of functional immunosuppression that, is partly independent of other measured factors, then lower survival following tuberculosis is expected, even if analyses adjust appropriately for the other indicators. This would not imply cause.
Isoniazid preventive therapy, while reducing tuberculosis incidence in HIV-infected individuals, has no effect on overall survival [7] [8] [9] . Furthermore, without antiretrovirals, survival following HIV infection in developing countries with high tuberculosis rates is very similar to that in developed countries, where tuberculosis is relatively rare even among the HIV-infected [10, 11] . We explored the relationship between tuberculosis and survival among HIV-positive men working in South African gold mines.
This retrospective cohort study was based on data routinely kept by the mining company [11, 12] . Medical, demographic and personnel information were linked using unique industry numbers. HIV testing was done with counseling and consent and the database was confidential and unavailable to mine management. In 1992-1993, two systematic 10% samples of the miners were HIV tested. Tests were also done at sexually transmitted disease clinics and as clinically indicated on surgical, medical and tuberculosis wards. After excluding tests from medical and tuberculosis wards (to avoid inclusion of individuals in the cohort because they were ill), individuals with an interval of less than 3 years between the last negative and first positive test were included in the seroconverter cohort.
The tuberculosis control program includes annual chest radiograph screening and contact tracing, although most patients self-present to mine medical facilities. At least three sputum smear examinations are done (using fluorescent microscopy). One specimen is cultured, using Bactec. All patients are treated using directly observed therapy (2 months isoniazid, rifampicin, pyrazinamide and ethambutol followed by 4 months isoniazid and rifampicin). Treatment is adapted for those with drug resistance. In this study, tuberculosis cases were sputum smear and/or culture positive for Mycobacterium tuberculosis or were diagnosed as having pulmonary tuberculosis on the basis of clinical features, chest radiography and response to antituberculosis treatment.
The date of seroconversion was taken as the midpoint of the seroconversion interval. Survival analysis and Cox proportional hazards were used, and patients entered the analysis on the date of the first positive test. The analysis was censored when men left the mines (plus 6 months to allow for late death registration and men leaving with terminal illness). Follow-up continued until December 2004. Tuberculosis was treated as a time varying covariate.
Only the first episode of pulmonary tuberculosis since seroconversion to HIV was considered. The effects of tuberculosis on subsequent survival were assessed, including any variation by age and by time since seroconversion. To exclude any direct effects of tuberculosis on mortality, the analysis was repeated after excluding a 1-year period from tuberculosis diagnosis. Cause of death was recorded, when known, from autopsies, mine records and death certificates [13] .
No antituberculosis prophylaxis was used at the time. Antiretroviral therapy was introduced in late 2004. The study was approved by the ethics committees of the University of Witwatersrand, South Africa, and the London School of Hygiene & Tropical Medicine, UK.
Overall, 1950 men with known dates of seroconversion were included (mean age 31 years), of whom 399 had an episode of pulmonary tuberculosis. There were 308 deaths, 111 after tuberculosis. The mortality rate after tuberculosis was greatly increased (Fig. 1) : hazard ratio ¼ 4.7 (95% confidence interval ¼ 3.7-6.1), adjusted for age at seroconversion, compared with men without tuberculosis. There were 52 deaths in the first year after tuberculosis diagnosis (22 due to tuberculosis, 10 unknown) and 59 thereafter (15 due to tuberculosis, nine unknown). Excluding the first year after tuberculosis, reduced the ratios slightly: age-adjusted hazard ratio ¼ 4.0 (95% CI ¼ 2.9-5.4). The relative survival after tuberculosis was similar in different age groups and in different periods after HIV infection: age-adjusted hazard ratio ¼ 6.3 (95% CI ¼ 4.0-9.8) for less than 4 years; 4.4 (2.8-6.9) for 4-7 years and 4.7 (2.0-11.2) for 7 years or more after seroconversion. This suggests that those who develop tuberculosis -at any point since seroconversion -are likely to be those in whom HIV is progressing most quickly.
In industrialized countries, individuals with known dates of seroconversion to HIV who developed tuberculosis had lower survival than those who did not, but similarly low subsequent survival was seen with other AIDSdefining opportunistic infections in individuals infected for the same length of time [14] . Getting an AIDSdefining opportunistic infection is probably a better marker of the degree of HIV disease progression than are laboratory markers.
We present the only other study of survival following tuberculosis in a cohort with known dates of seroconversion to HIV, and the only one from a high tuberculosis incidence setting. In this setting, not getting tuberculosis is probably a sign of a well functioning immune system, and mortality rates in this group were relatively low. By contrast, mortality rates following tuberculosis in the HIV-infected, however soon after seroconversion the tuberculosis occurred, were similar to mortality rates seen in those infected with HIV for more than 10 years [11, 15] . The increase in mortality following tuberculosis was partly due to tuberculosis itself, both during the episode and later.
In the cohort, 20% experienced at least one episode of tuberculosis. Yet, as we have already shown that overall survival from seroconversion in this cohort is similar to that in the CASCADE study in which 2% got tuberculosis [14] , it is likely that the high mortality following tuberculosis largely reflects the level of functional immunosuppression and does not add significantly to progression. However, it does support the use of tuberculosis as an appropriate indicator for starting antiretroviral therapy. To assess the effect of obesity on CD4 cell counts, we estimated the association of time-updated BMI categories with CD4 changes among 1001 documented HIV seroconverters. During the pre-highly active antiretroviral therapy (HAART) era, a higher BMI was associated with less reduction in CD4 cell counts over time. However during the HAARTera, obese versus normal weight patients had smaller increases in CD4 cell counts (R69 versus R116 cells, P U 0.01). Lower CD4 cell counts may now be another adverse consequence of obesity.
The prevalence of obesity among HIV-infected persons is increasing [1] [2] [3] . Although excess weight is associated with several medical conditions [4, 5] , its impact on immune status remains largely unknown. In the prehighly active antiretroviral therapy (HAART) era, studies showed that being underweight was associated with lower CD4 cell counts and shorter survival, whereas higher weights were associated with slower HIV progression [6] [7] [8] [9] [10] . However, since HAART has become available and wasting less frequent [2, 3, 11, 12] , the impact of weight may differ.
We investigated the relationship between longitudinal weight measurements and CD4 cell counts among 1001 documented HIV seroconverters using the US Military HIV Natural History Study . Participants had a seroconversion window of 3 years or less (mean 15.8 months) and biannual weight measurements and CD4 cell counts.
Weight was categorized using BMI, kg/m 2 , as previously described [13, 14] .
Using longitudinal linear mixed models with a random intercept for each participant, regressions for change from HIV diagnosis in CD4 cell count were fitted. All models were adjusted for age, sex, race, length of seroconversion window, baseline CD4 and HIV RNA level, timeupdated cumulative time on antiretroviral therapy (ART) and HAART, BMI category, and follow-up visit. As several characteristics varied by era, analyses were performed separately for those diagnosed in the pre-HAARTand HAARTeras (cut-off point 1 January 1996). Among participants diagnosed in the HAART era, additional analyses on change in CD4 cell count before and then after HAART initiation were performed (SAS version 9.1; SAS Institute, Inc., Cary, North Carolina, USA).
Of 1001 HIV seroconverters, 400 (40%, mean follow-up 5.1 years) were overweight, 84 (8%, mean follow-up 4.5 years) obese, and 12 (1%, mean follow-up 4.1 years) were underweight at HIV diagnosis. Mean age was 29 years; 96% were men; 45% were whites and 40% were African-Americans; 61% were diagnosed in the HAART era.
Among HIV-infected seroconverters diagnosed in the pre-HAARTera (n ¼ 394, mean follow-up 6.5 years), the estimated mean postdiagnosis decreases in CD4 cell counts were less as the BMI category increased, À158, À125, À95, and À50 cells/ml, respectively (P < 0.001; Table 1 ). Compared with normal weight patients, overweight (P ¼ 0.005) and obese (P < 0.001) patients had smaller reductions in the CD4 cell count.
Among HIV-infected patients diagnosed in the HAART era (n ¼ 607, mean follow-up 4.2 years), the estimated mean postdiagnosis change in CD4 cell count was À1, þ103, þ116, and þ69 cells/ml, respectively (P < 0.001; Table 1 ). Obese HIV patients compared with those with normal weight had significantly smaller increases in CD4 cell count (P ¼ 0.01). Those who were underweight had a mean decline in the CD4 cell count, whereas those with normal weight averaged an increase (À1 versus 103 cells/ml, P ¼ 0.004).
Among patients diagnosed in the HAARTera, the impact of weight on CD4 responses was also evaluated before and after HAART initiation. Prior to initiation, CD4 cell counts declined in each BMI category (À153, À55, À57, and À76 cells/ml across increasing BMI categories, P ¼ 0.33), although no comparisons between normal weight and the other weight categories were statistically different. After HAART initiation, CD4 cell counts increased in each weight category (þ127, þ210, þ230, and þ188, respectively, P ¼ 0.01). Obese compared with overweight HIV patients gained significantly fewer CD4 cells after HAART initiation (42 cells less, P ¼ 0.008).
Analyses were also performed for change in the CD4 percentage with similar findings for both the pre-HAART and HAART eras ( Table 1 ).
Our study demonstrates that weight appears to affect CD4 cell counts over the course of HIV infection. Although higher BMI categories were associated with less reduction in CD4 cell counts during the pre-HAART era, excess weight was not similarly beneficial during the HAART era, with obese patients achieving smaller CD4 cell count and percentage increases over time. These data suggest that obesity may be associated with poorer immunologic recovery among HIV in the setting of HAART availability.
Concurrent with our findings, prior studies during the pre-HAART era found that higher weights were associated with more robust CD4 cell counts as well as slower HIV progression and improved survival [6, 8, 9] . It has been hypothesized that nutritional reserves, in the form of fat stores, may prevent severe wasting and lean body loss at the time of AIDS-related crises and may help preserve immune counts [7] .
As the incidence of wasting and end-stage AIDS has significantly declined due to HAARTuse [2, 3, 11, 12] , the potential benefits of maintaining higher weights may have changed. Our study was unique in that it also evaluated the impact of weight on CD4 cell counts after the advent of HAART. To our knowledge, there has only been one similar study in the late HAART era, which showed no effect of obesity on CD4 cell counts; however, this study was limited by its cross-sectional design and lack of data on HIV seroconversion dates [15] . In our longitudinal study, we found that, among HIV seroconverters diagnosed in the HAARTera, obese patients had smaller increases in CD4 cell counts and percentages than normal weight patients. Our data suggest that the advantages of excessive weight may no longer be present among HIV patients who have access to HAART and robust CD4 cell counts, and that obesity may adversely affect CD4 recovery; further studies are needed to confirm our findings.
Possible mechanisms for the association between obesity and less robust CD4 cell counts include that obesity is associated with elevated levels of inflammatory markers (e.g. C-reactive protein and interleukin-6) and adipokines that may have negative immune effects [16] [17] [18] [19] [20] . It is also plausible that excess weight may negatively affect antiretroviral drug levels as lipophilic drugs have a greater volume of distribution among obese patients. Further studies examining functional immune parameters, biomarkers, and drug levels are needed.
In summary, although higher weight categories were associated with less reduction in CD4 cell counts in the pre-HAARTera, excessive weight (BMI>30 kg/m 2 ) was not beneficial in the HAARTera and was associated with smaller CD4 cell count increases. These data suggest that HIV providers should be cognizant of the potential negative effects of obesity among their patients, including the potential adverse effects on CD4 cell counts. Weight monitoring and maintenance programs may be useful components of HIV clinical care visits. Biliary tract complications after liver transplantation represent a source of morbidity and mortality. Performing an analysis to evaluate whether HIV infection and its related comorbidities, such as HIV-related cholangiopathy, could be an unknown risk factor for biliary stricture, we found that HIVpositivity could lead to greater susceptibility to biliary damage. The pathogenesis of the damage seems to involve the pretransplant immunological status and the number and type of posttransplant infections, although further studies are needed.
HIV-related cholangiopathy has been described as a disease typically diagnosed by the finding of an anicteric cholestatic liver enzyme profile often associated with a lowered CD4 lymphocyte count [1, 2] . The pathogenesis of the biliary injury is still unknown, even if some important findings are emerging. Considering biliary tract complications after liver transplantation, it is well known that they still remain a common source of morbidity and mortality, representing the true 'Achilles heel' of this procedure [3] [4] [5] . We performed an analysis to evaluate whether HIV infection and its related comorbidities could be an unknown risk factor for biliary stricture. We analyzed all the groups of patients who underwent liver transplantation in our centre, comparing the group of patients with biliary stricture with those in whom it did not develop. We standardized the study for timing, from June 2003 (first liver transplantation in an HIV-positive patient) to July 2009; underlying disease (selected from the group of HIV-positive patients); minimum follow-up (>3 months); and biliary stricture cause (only the idiopathic ones were considered, ruling out the patients with a hepatic artery thrombosis or stenosis before the biliary stricture development). We obtained 195 suitable patients and a total of 49 cases of biliary stricture; we then analyzed HIVas a possible categorical variable predictive for biliary stricture and we found that HIV positivity was significant as a possible risk factor for biliary stricture [HIV-positive/ HIV-negative biliary stricture 8(15)/41(180); P ¼ 0.014; Table 1 ].
Considering the HIV-positive patients 15 out of the 18 had a follow-up longer than 3 months; they were all men, with a mean age at the time of liver transplantation of 44 AE 5 years. The model for end stage liver disease mean value at the time of liver transplantation was 18 AE 6. The leading cause of end stage liver disease was viral hepatitis C (HCV)-related in nine patients, hepatitis B virus (HBV)related in two patients and HCV þ HBV-related in four patients. The mean follow-up was 28 AE 19 months.
In the period taken into account, eight out of the 15 patients developed a biliary anastomosis stricture. The mean time after liver transplantation was 10 AE 9 months.
Regarding the biliary reconstruction, 12 out of the 15 patients underwent duct-to-duct anastomosis and the other three patients underwent hepaticojejunostomy for considerable disparity in size. In three cases undergoing duct-to-duct anastomosis, a T-tube was placed due to the small calibre of the biliary ducts.
Diagnosis of biliary stricture was made by the finding of a cholestasis pattern (alkaline phosphatase more than 129 U/l; normal range 35-129 U/l); g-glutamyl transpeptidases more than 50 U/L (normal range 11-50 U/L); bilirubin more than 1.2 mg/dl (normal range 0.2-1.2 mg/dl), followed by performing Doppler ultrasound as the first-line investigation choice, to rule out the presence of hepatic artery thrombosis or stenosis [6] . If dilatation was undetectable at ultrasound, and other major causes of cholestasis, such as acute cellular rejection, drug toxicity, recurrent hepatitis, etc., were ruled out, we proceeded with a second-line investigation by magnetic resonance cholangiography [7] .
Uncomplicated anastomotic strictures were treated with endoscopic or percutaneous balloon dilatation and stenting [8, 9] , depending on the type of anastomosis performed, duct-to-duct anastomosis patients underwent endoscopy and hepaticojejunostomy anastomosis patients underwent percutaneous treatment. Three out of the eight patients needed surgical revision of the anastomosis by means of a hepaticojejunostomy because of percutaneous treatment failure, more than three procedures occurred without a significant improvement in the cholestasis pattern and episodes of cholangitis occurred.
We performed a univariate analysis of the possible risk factors for biliary stricture, restricted to the group of HIVpositive patients, and found that no variable had a statistical significance (Table 1) .
In our experience, only HIV positivity represented a significant risk factor for biliary stricture development.
Analyzing the group of HIV-positive patients, no variables were found to be statistically significant as risk factors for biliary stricture, probably due to the small sample of patients, but we believe that some reasonable considerations can emerge from the data ( Table 1 ). The HIV-positive patients who developed biliary stricture had major episodes of reactivation of herpetic viruses during the postliver transplantation follow-up. The CD4 lymphocyte count before liver transplantation was slightly lower in patients who developed biliary stricture and, after liver transplantation, these patients were exposed to a value of CD4 T-cell count less than 200 for a longer time and with lowest absolute value, in comparison to patients who did not develop biliary stricture.
Other reports suggest that HIV by itself could lead to greater susceptibility to biliary damage [10, 11] .
In our centre, highly-active antiretroviral therapy (HAART) was delayed until transaminases had normalized to lower than three times the upper limit of the normal range, bilirubin was lower than 2 mg/dl and stable calcineurin inhibitor blood levels within the desired range were established. It is well known that HAART therapy stimulates the generationof naive T cells frommemory cells, increasing CD4 T-cell counts [12] . In the period previous to HAARTreintroduction, we can therefore hypothesize that the high level of immunosuppression, expressed by the low CD4 T-cell count, could have triggered an unknown mechanism similar to HIV-related cholangiopathy, leading to an increased biliary stricture susceptibility.
The aim of the present study is to show that HIV-positive recipients of liver transplantation have an increased susceptibility to biliary stricture. The small number of cases analyzed does not allow us to define a cause for this mechanism with any certainty, nor to define whether this mechanism can coincide with HIV-related cholangiopathy. We therefore believe that further studies on this topic are necessary, especially regarding the pretransplant immunological status (number of CD4 cells), and the number and type of posttransplant infections, correlated with the incidence of biliary strictures in HIV-positive recipients.
In conclusion, although other studies will help to define the pathogenesis of HIV cholangiopathy and its implication in liver transplantation outcome, we believe that early resumption of postliver transplantation HAART therapy, appropriate prophylaxis for herpes virus reactivation, and biliary reconstruction by hepaticojejunostomy or by the use of a T-tube in the duct-to-duct anastomosis as the firstline choice could help to reduce the incidence of biliary stricture in HIV-positive recipients.
